These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 36933660)

  • 1. Monitoring adherence and abstinence of cannabis use disorder patients: Profile identification and relationship with long-term treatment outcomes.
    Dacosta-Sánchez D; Fernández-Calderón F; Blanc-Molina A; Díaz-Batanero C; Lozano OM
    J Subst Use Addict Treat; 2023 May; 148():209019. PubMed ID: 36933660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychosocial interventions for cannabis use disorder.
    Gates PJ; Sabioni P; Copeland J; Le Foll B; Gowing L
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD005336. PubMed ID: 27149547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults.
    Gray KM; Sonne SC; McClure EA; Ghitza UE; Matthews AG; McRae-Clark AL; Carroll KM; Potter JS; Wiest K; Mooney LJ; Hasson A; Walsh SL; Lofwall MR; Babalonis S; Lindblad RW; Sparenborg S; Wahle A; King JS; Baker NL; Tomko RL; Haynes LF; Vandrey RG; Levin FR
    Drug Alcohol Depend; 2017 Aug; 177():249-257. PubMed ID: 28623823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Race, psychosocial characteristics, and treatment outcomes among individuals undergoing treatment for cannabis use disorder: A latent profile analysis based on preferred method of using cannabis.
    Ullrich HS; Torbati A; Fan W; Arbona C; Cano MA; Essa S; Harvey L; Vaughan EL; de Dios MA
    J Subst Abuse Treat; 2021 Dec; 131():108561. PubMed ID: 34275690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Goal commitment predicts cannabis use for adolescents in treatment.
    Kaminer Y; Ohannessian CM; Burke RH
    Subst Abus; 2019; 40(4):496-500. PubMed ID: 30810498
    [No Abstract]   [Full Text] [Related]  

  • 6. Low Pretreatment Impulsivity and High Medication Adherence Increase the Odds of Abstinence in a Trial of N-Acetylcysteine in Adolescents with Cannabis Use Disorder.
    Bentzley JP; Tomko RL; Gray KM
    J Subst Abuse Treat; 2016 Apr; 63():72-7. PubMed ID: 26827257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A method to achieve extended cannabis abstinence in cannabis dependent patients with schizophrenia and non-psychiatric controls.
    Rabin RA; Kozak K; Zakzanis KK; Remington G; Stefan C; Budney AJ; George TP
    Schizophr Res; 2018 Apr; 194():47-54. PubMed ID: 28506704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cannabis cessation interventions offered to young French users: predictors of follow-up].
    Abdoul H; Le Faou AL; Bouchez J; Touzeau D; Lagrue G
    Encephale; 2012 Apr; 38(2):141-8. PubMed ID: 22516272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of extended cannabis abstinence on clinical symptoms in cannabis dependent schizophrenia patients versus non-psychiatric controls.
    Rabin RA; Kozak K; Zakzanis KK; Remington G; George TP
    Schizophr Res; 2018 Apr; 194():55-61. PubMed ID: 28285022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Motivations for cannabis cessation, coping and adaptation strategies, and perceived benefits: impact on cannabis use relapse and abstinence].
    Chauchard E; Septfons A; Chabrol H
    Encephale; 2013 Dec; 39(6):385-92. PubMed ID: 23928064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Depressive symptoms and cannabis use in a placebo-controlled trial of N-Acetylcysteine for adult cannabis use disorder.
    Tomko RL; Baker NL; Hood CO; Gilmore AK; McClure EA; Squeglia LM; McRae-Clark AL; Sonne SC; Gray KM
    Psychopharmacology (Berl); 2020 Feb; 237(2):479-490. PubMed ID: 31712969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CANDIS treatment program for cannabis use disorders: findings from a randomized multi-site translational trial.
    Hoch E; Bühringer G; Pixa A; Dittmer K; Henker J; Seifert A; Wittchen HU
    Drug Alcohol Depend; 2014 Jan; 134():185-193. PubMed ID: 24176199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abstinence and reduced frequency of use are associated with improvements in quality of life among treatment-seekers with cannabis use disorder.
    Brezing CA; Choi CJ; Pavlicova M; Brooks D; Mahony AL; Mariani JJ; Levin FR
    Am J Addict; 2018 Mar; 27(2):101-107. PubMed ID: 29457671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and correlates of treatment utilization among adults with cannabis use disorder in the United States.
    Wu LT; Zhu H; Mannelli P; Swartz MS
    Drug Alcohol Depend; 2017 Aug; 177():153-162. PubMed ID: 28599214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treating cannabis use disorder: Exploring a treatment as needed model with 34-month follow-up.
    Stephens RS; Walker R; DeMarce J; Lozano BE; Rowland J; Walker D; Roffman RA
    J Subst Abuse Treat; 2020 Oct; 117():108088. PubMed ID: 32811637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identifying HIV care enrollees at-risk for cannabis use disorder.
    Hartzler B; Carlini BH; Newville H; Crane HM; Eron JJ; Geng EH; Mathews WC; Mayer KH; Moore RD; Mugavero MJ; Napravnik S; Rodriguez B; Donovan DM
    AIDS Care; 2017 Jul; 29(7):846-850. PubMed ID: 28006972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Who responds best to text-delivered cannabis use disorder treatment? A randomized clinical trial with young adults.
    Mason MJ; Zaharakis NM; Moore M; Brown A; Garcia C; Seibers A; Stephens C
    Psychol Addict Behav; 2018 Nov; 32(7):699-709. PubMed ID: 30265057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alcohol substitution during one month of cannabis abstinence among non-treatment seeking youth.
    Schuster RM; Potter K; Lamberth E; Rychik N; Hareli M; Allen S; Broos HC; Mustoe A; Gilman JM; Pachas G; Evins AE
    Prog Neuropsychopharmacol Biol Psychiatry; 2021 Apr; 107():110205. PubMed ID: 33309538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A contingency management method for 30-days abstinence in non-treatment seeking young adult cannabis users.
    Schuster RM; Hanly A; Gilman J; Budney A; Vandrey R; Evins AE
    Drug Alcohol Depend; 2016 Oct; 167():199-206. PubMed ID: 27590742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review of outcome domains and measures used in psychosocial and pharmacological treatment trials for cannabis use disorder.
    Lee DC; Schlienz NJ; Peters EN; Dworkin RH; Turk DC; Strain EC; Vandrey R
    Drug Alcohol Depend; 2019 Jan; 194():500-517. PubMed ID: 30530238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.